. ▁ ▁However , ▁initial ▁clin ical ▁tri als ▁using ▁broad ▁spectrum ▁M MP ▁in hib itors ▁did ▁show ▁some ▁positive ▁results . ▁Ph ase ▁I ▁clin ical ▁tri als ▁showed ▁that ▁M MP ▁in hib itors ▁are ▁generally ▁safe ▁with ▁minimal ▁ad verse ▁side ▁effects . ▁Additionally , ▁tri als ▁with ▁mar im ast at ▁did ▁show ▁a ▁slight ▁increase ▁in ▁surv ival ▁of ▁patients ▁with ▁g astr ic ▁or ▁pan cre atic ▁cancer . ▁ ▁Vari ous ▁research ▁groups ▁have ▁already ▁suggested ▁many ▁strateg ies ▁for ▁impro ving ▁the ▁effect iveness ▁of ▁M MP ▁in hib itors ▁in ▁cancer ▁treatment . ▁ ▁First , ▁highly ▁specific ▁M MP ▁in hib itors ▁could ▁be ▁used ▁to ▁target ▁the ▁functions ▁of ▁specific ▁M MP s , ▁which ▁should ▁allow ▁do ctors ▁to ▁increase ▁the ▁treatment ▁dos age ▁while ▁minim izing ▁ad verse ▁side ▁effects . ▁M MP ▁in hib itors ▁could ▁also ▁be ▁admin ister ed ▁along ▁with ▁c yt ot ox ic ▁agents ▁or ▁other ▁protein ase ▁in hib itors . ▁Finally , ▁M MP ▁in hib itors ▁could ▁be ▁used ▁during ▁earlier ▁stages ▁of ▁cancer ▁to ▁prevent ▁invasion ▁and ▁met ast asis . ▁ ▁Additionally , ▁tum or ▁over expression ▁of ▁M MP s ▁can ▁be ▁used ▁to ▁potentially ▁target ▁the ▁release ▁of ▁chem other ape ut ic ▁agents ▁specifically ▁to ▁tum or ▁sites . ▁For ▁instance , ▁c yt ot ox ic ▁agents ▁or ▁si R NA ▁could ▁be ▁enc aps ulated ▁in ▁li pos om es ▁or ▁vir al